These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 39127699)

  • 1. Recurrent adamantinomatous craniopharyngiomas show MAPK pathway activation, clonal evolution and rare TP53-loss-mediated malignant progression.
    Apps JR; Gonzalez-Meljem JM; Guiho R; Pickles JC; Prince E; Schwalbe E; Joshi N; Stone TJ; Ogunbiyi O; Chalker J; Bassey A; Otto G; Davies R; Hughes D; Brandner S; Tan E; Lee V; Hayhurst C; Kline C; Castellano S; Hankinson T; Deutschbein T; Jacques TS; Martinez-Barbera JP
    Acta Neuropathol Commun; 2024 Aug; 12(1):127. PubMed ID: 39127699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target.
    Apps JR; Carreno G; Gonzalez-Meljem JM; Haston S; Guiho R; Cooper JE; Manshaei S; Jani N; Hölsken A; Pettorini B; Beynon RJ; Simpson DM; Fraser HC; Hong Y; Hallang S; Stone TJ; Virasami A; Donson AM; Jones D; Aquilina K; Spoudeas H; Joshi AR; Grundy R; Storer LCD; Korbonits M; Hilton DA; Tossell K; Thavaraj S; Ungless MA; Gil J; Buslei R; Hankinson T; Hargrave D; Goding C; Andoniadou CL; Brogan P; Jacques TS; Williams HJ; Martinez-Barbera JP
    Acta Neuropathol; 2018 May; 135(5):757-777. PubMed ID: 29541918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma.
    Goschzik T; Gessi M; Dreschmann V; Gebhardt U; Wang L; Yamaguchi S; Wheeler DA; Lauriola L; Lau CC; Müller HL; Pietsch T
    J Neuropathol Exp Neurol; 2017 Feb; 76(2):126-134. PubMed ID: 28069929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and cellular pathogenesis of adamantinomatous craniopharyngioma.
    Martinez-Barbera JP
    Neuropathol Appl Neurobiol; 2015 Oct; 41(6):721-32. PubMed ID: 25611703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.
    Coy S; Rashid R; Lin JR; Du Z; Donson AM; Hankinson TC; Foreman NK; Manley PE; Kieran MW; Reardon DA; Sorger PK; Santagata S
    Neuro Oncol; 2018 Jul; 20(8):1101-1112. PubMed ID: 29509940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological Behaviour of Craniopharyngiomas.
    Martinez-Barbera JP; Andoniadou CL
    Neuroendocrinology; 2020; 110(9-10):797-804. PubMed ID: 32126562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adamantinomatous craniopharyngioma: moving toward targeted therapies.
    Hengartner AC; Prince E; Vijmasi T; Hankinson TC
    Neurosurg Focus; 2020 Jan; 48(1):E7. PubMed ID: 31896087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases.
    Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Suri V; Sarkar C; Jagdevan A; Sharma BS; Sharma MC
    J Neurooncol; 2017 Jul; 133(3):487-495. PubMed ID: 28500561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of novel CTNNB1 mutation in Craniopharyngioma by whole-genome sequencing.
    He J; Zeng Z; Wang Y; Deng J; Tang X; Liu F; Huang J; Chen H; Liang R; Zan X; Liu Z; Tong A; Guo G; Xu J; Zhu X; Zhou L; Peng Y
    Mol Cancer; 2021 Dec; 20(1):168. PubMed ID: 34922552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 60 YEARS OF NEUROENDOCRINOLOGY: Biology of human craniopharyngioma: lessons from mouse models.
    Martinez-Barbera JP
    J Endocrinol; 2015 Aug; 226(2):T161-72. PubMed ID: 25926515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma.
    Andoniadou CL; Gaston-Massuet C; Reddy R; Schneider RP; Blasco MA; Le Tissier P; Jacques TS; Pevny LH; Dattani MT; Martinez-Barbera JP
    Acta Neuropathol; 2012 Aug; 124(2):259-71. PubMed ID: 22349813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative immunohistochemical expression of β-catenin, EGFR, ErbB2, and p63 in adamantinomatous and papillary craniopharyngiomas.
    Esheba GE; Hassan AA
    J Egypt Natl Canc Inst; 2015 Sep; 27(3):139-45. PubMed ID: 26198262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the Canonical Wnt Pathway Activation on the Pathogenesis and Prognosis of Adamantinomatous Craniopharyngiomas.
    Jucá CEB; Colli LM; Martins CS; Campanini ML; Paixão B; Jucá RV; Saggioro FP; de Oliveira RS; Moreira AC; Machado HR; Neder L; Antonini SR; de Castro M
    Horm Metab Res; 2018 Jul; 50(7):575-581. PubMed ID: 29625497
    [No Abstract]   [Full Text] [Related]  

  • 14. High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas.
    Yoshimoto K; Hatae R; Suzuki SO; Hata N; Kuga D; Akagi Y; Amemiya T; Sangatsuda Y; Mukae N; Mizoguchi M; Iwaki T; Iihara K
    Neuropathology; 2018 Feb; 38(1):3-10. PubMed ID: 28840946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Wnt signalling cascade and the adherens junction complex in craniopharyngioma tumorigenesis.
    Preda V; Larkin SJ; Karavitaki N; Ansorge O; Grossman AB
    Endocr Pathol; 2015 Mar; 26(1):1-8. PubMed ID: 25355426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma.
    Larkin SJ; Preda V; Karavitaki N; Grossman A; Ansorge O
    Acta Neuropathol; 2014; 127(6):927-9. PubMed ID: 24715106
    [No Abstract]   [Full Text] [Related]  

  • 17. Do craniopharyngioma molecular signatures correlate with clinical characteristics?
    Omay SB; Chen YN; Almeida JP; Ruiz-Treviño AS; Boockvar JA; Stieg PE; Greenfield JP; Souweidane MM; Kacker A; Pisapia DJ; Anand VK; Schwartz TH
    J Neurosurg; 2018 May; 128(5):1473-1478. PubMed ID: 28707994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular pathology of adamantinomatous craniopharyngioma: review and opportunities for practice.
    Apps JR; Martinez-Barbera JP
    Neurosurg Focus; 2016 Dec; 41(6):E4. PubMed ID: 27903120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential evolution of neurosurgical treatment paradigms for craniopharyngioma based on genomic and transcriptomic characteristics.
    Robinson LC; Santagata S; Hankinson TC
    Neurosurg Focus; 2016 Dec; 41(6):E3. PubMed ID: 27903126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible linkage between specific histological structures and aberrant reactivation of the Wnt pathway in adamantinomatous craniopharyngioma.
    Kato K; Nakatani Y; Kanno H; Inayama Y; Ijiri R; Nagahara N; Miyake T; Tanaka M; Ito Y; Aida N; Tachibana K; Sekido K; Tanaka Y
    J Pathol; 2004 Jul; 203(3):814-21. PubMed ID: 15221941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.